Fusion Antibodies PLC Director/PDMR Shareholding (7785N)
26 Septiembre 2019 - 3:54AM
UK Regulatory
TIDMFAB
RNS Number : 7785N
Fusion Antibodies PLC
26 September 2019
Fusion Antibodies plc
("Fusion" or the "Company")
Director/PDMR Shareholding
Fusion Antibodies plc (AIM: FAB), a contract research
organisation providing a range of antibody engineering services for
the development of antibodies for both therapeutic drug and
diagnostic applications, has been notified that, on 25 September
2019, Alan Mawson, Non-Executive Director, purchased 15,000
ordinary shares in the Company ("Ordinary Shares") into his pension
fund at a price of 65 pence per Ordinary Share. Following this
purchase, Alan Mawson has a direct and indirect interest in 68,988
Ordinary Shares, representing approximately 0.31 per cent. of the
Company's issued share capital. Alan Mawson is also a Non-Executive
Director of Clarendon Fund Managers Limited ("Clarendon") and sits
on Clarendon's investment committee. Clarendon is the fund manager
for Nitech Growth Fund LP which holds 358,850 Ordinary Shares and
Viridian Growth Fund LP which holds 1,831,500 Ordinary Shares.
The following notification, made in accordance with the
requirements of the EU Market Abuse Regulation, gives further
details.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Alan Mawson
------------------------- ------------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position/status Non-Executive Director
------------------------- ------------------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------- ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Fusion Antibodies plc
------------------------- ------------------------------------------------
b) LEI 213800KBAYRC9VOQ9V39
------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of Ordinary shares of 4p each in Fusion Antibodies
the financial plc
instrument, type Identification code (ISIN) for Fusion
of instrument Antibodies plc ordinary shares:
Identification GB00BDQZGK16
code
------------------------- ------------------------------------------------
b) Nature of the Purchase of shares
transaction
------------------------- ------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
65p 15,000
----------
------------------------- ------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
------------------------- ------------------------------------------------
e) Date of the transaction 26 September 2019
------------------------- ------------------------------------------------
f) Place of the transaction London Stock Exchange, XLON
------------------------- ------------------------------------------------
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Via Walbrook PR
Officer
James Fair, Chief Financial
Officer
Allenby Capital Limited Tel: +44 (0)20 3328 5656
James Reeve / Asha Chotai
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Anna Dunphy Mob: +44 (0)7876 741 001
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on
18 December 2017. Fusion provides a broad range of services in
antibody generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx(TM) platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 150 humanisation projects for its international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's
University Belfast. The Company's mission is to enable
pharmaceutical and diagnostic companies to develop innovative
products in a timely and cost-effective manner for the benefit of
the global healthcare industry. Fusion Antibodies provides a broad
range of services in antibody generation, development, production,
characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the
latest technological advances with cutting edge science to deliver
new platforms that will enable Pharma and Biotechs get to the
clinic faster and ultimately speed up the drug development
process.
The global monoclonal antibody therapeutics market was valued at
$95.5 billion in 2017 and is forecast to surpass $174.2 billion in
2026, an increase at a CAGR of between 6.9 per cent. for the period
2018 to 2026. In 2018, seven of the world's ten top selling drugs
were antibody-based therapeutics with the combined annual sales of
these drugs exceeding $62 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHSESSAMFUSEIU
(END) Dow Jones Newswires
September 26, 2019 04:54 ET (08:54 GMT)
Fusion Antibodies (LSE:FAB)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Fusion Antibodies (LSE:FAB)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024